Review
Open access
Sep 2026
CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection
Claudin 18.2 (CLDN18.2) is expressed in a subset of pancreatic ductal adenocarcinomas (PDACs) and is under clinical development as a target for monoclonal antibodies, antibody‐drug conjugates, immune‐cell engagers, and chimeric antigen receptor (CAR) T‐cell therapies. The testing and clinical‐development pathways...
Ru-Yu Tan, Zhe-Xin Zhang, Jia-Xing Wang et al.
· Clinical and Translational D... · 0 citations